Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NOS3 | P29474 | 2/20 | 0.46 |
| ▸ | NOS2 | P35228 | 2/20 | 0.46 |
| ▸ | NOS1 | P29475 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | DNM2 | P50570 | 1/20 | 0.40 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.33 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | NCF1 | P14598 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12250747 | 0.78 | NOS3 (0.40) | MEN1KMT2ATSHRNOS3NOS2 | |
| SCHEMBL12250731 | 0.78 | NOS2 (0.40) | MEN1KMT2ATSHRNOS3NOS2 | |
| SCHEMBL16941548 | 0.78 | NOS3 (0.40) | MEN1KMT2ATSHRNOS3NOS2 | |
| SCHEMBL30336057 | 0.76 | MEN1 (1.00) | MEN1KMT2ATSHRNOS3NOS2 | |
| SCHEMBL9977693 | 0.76 | KMT2A (0.57) | MEN1KMT2ATSHRTAAR1DNM2 | |
| SCHEMBL6463426 | 0.76 | KMT2A (0.57) | MEN1KMT2ATSHRNOS3NOS2 | |
| SCHEMBL432253 | 0.76 | MEN1 (1.00) | MEN1KMT2ATSHRNOS3NOS2 | |
| SCHEMBL4925827 | 0.76 | MEN1 (0.52) | MEN1KMT2ATSHRNOS3NOS2 | |
| SCHEMBL2757263 | 0.75 | KMT2A (0.61) | MEN1KMT2ATSHRTAAR1DNM2 | |
| SCHEMBL12250813 | 0.75 | KMT2A (0.44) | MEN1KMT2ANOS3NOS2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3211123-B1 | HORIZONTAL METHOD OF ELECTROLESS METAL PLATING OF SUBSTRATES WITH IONIC CATALYSTS | ROHM & HAAS ELECT MAT (US) | 2019-01-09 | — | — | EP | claimed |
| US-20170251557-A1 | HORIZONTAL METHOD OF ELECTROLESS METAL PLATING OF SUBSTRATES WITH IONIC CATALYSTS | ROHM & HAAS ELECT MAT (US) | 2017-08-31 | — | — | US | claimed |
| EP-3211123-A1 | HORIZONTAL METHOD OF ELECTROLESS METAL PLATING OF SUBSTRATES WITH IONIC CATALYSTS | Rohm and Haas Electronic Materials LLC (US) | 2017-08-30 | — | — | EP | claimed |
| CN-102605356-B | Plating catalyst and method | ROHM & HAAS ELECT MAT | 2014-11-19 | — | — | CN | claimed |
| US-8591636-B2 | Plating catalyst and method | ROHM AND HAAS ELECTRONICS MATERIALS LLC (US) | 2013-11-26 | — | — | US | claimed |
| CN-107130230-B | The horizontal process of the electroless metal plating of substrate with ionic catalyst | 罗门哈斯电子材料有限责任公司 | 2019-08-27 | — | — | CN | disclosed |
| EP-3211123-B1 | HORIZONTAL METHOD OF ELECTROLESS METAL PLATING OF SUBSTRATES WITH IONIC CATALYSTS | ROHM & HAAS ELECT MAT (US) | 2019-01-09 | — | — | EP | disclosed |
| EP-2465974-B1 | Plating catalyst and method | ROHM & HAAS ELECT MAT (US) | 2018-11-28 | — | — | EP | disclosed |
| CN-107130230-A | The horizontal process of the electroless metal plating of substrate with ionic catalyst | 罗门哈斯电子材料有限责任公司 | 2017-09-05 | — | — | CN | disclosed |
| US-20170251557-A1 | HORIZONTAL METHOD OF ELECTROLESS METAL PLATING OF SUBSTRATES WITH IONIC CATALYSTS | ROHM & HAAS ELECT MAT (US) | 2017-08-31 | — | — | US | disclosed |
| EP-3211123-A1 | HORIZONTAL METHOD OF ELECTROLESS METAL PLATING OF SUBSTRATES WITH IONIC CATALYSTS | Rohm and Haas Electronic Materials LLC (US) | 2017-08-30 | — | — | EP | disclosed |
| US-8961669-B2 | Plating catalyst and method | ROHM AND HAAS ELECTRONIC MATERIALS LLC (US) | 2015-02-24 | — | — | US | disclosed |
| EP-2195311-B1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-03-23 | — | — | EP | disclosed |
| US-20110065683-A1 | TRISUBSTITUTED PYRAZOLES AS ACETYLCHOLINE RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-17 | — | — | US | disclosed |
| US-20110046170-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-02-24 | — | — | US | disclosed |
| US-20110046170-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-02-24 | — | — | US | disclosed |
| WO-2009109907-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009024905-A1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-02-26 | — | — | WO | disclosed |
| CN-1090189-C | pyrazolopyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2002-09-04 | — | — | CN | disclosed |
| CN-1205009-A | Pyrazolopyrimidines type compound | JANSSEN PHARMACEUTICA NV (BE) | 1999-01-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065683-A1 | TRISUBSTITUTED PYRAZOLES AS ACETYLCHOLINE RECEPTOR MODULATORS | CHRNA1, CHRM3, CHRNA5 | MEN1 4651/4885KMT2A 2308/4885TSHR 91/4885 |
| US-20110046170-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | TYMP, DPYD, ENTPD5 | MEN1 4570/4885KMT2A 3361/4885TSHR 2962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.